The product was initially developed as part of the European Institute of Technology Food project, SPIN, and was co-funded by the European Union. The University of Bologna designed and tested the product formulation and Targeting Gut Disease (TGD), a spin-off entrepreneurial company from the University of Bologna, commercialized it as a food supplement in February 2021. TGD’s next commercialization strategy step is to launch Eugedin Complex as a raw material to be used alone or in combination with other food supplements.
TARGETING GUT DISEASE
Targeting Gut Disease (TGD) S.r.l. is a young and dynamic company, highly specialised in the development of supplements with anti-inflammatory characteristics of natural origin, immunomodulatory and anti-dysbiotic. TGD was born in 2015 from the desire of its members to apply their interdisciplinary skills to produce a range of valid commercial products capable of improving chronic inflammatory conditions of the gastrointestinal tract. The company covers the entire process of developing new food supplements from in vitro research to clinical validation.
MEET THE DEVELOPMENT TEAM
Maria Chiara Valerii
TGD Founder and CEO
TGD Founder and CTO
TGD Technical Manager
PURPOSE OF THE PRODUCT
For centuries plant extracts have been and still are used by oriental medicine as healing elements. Using the theoretical foundations of the oriental medical tradition and reinforcing them with modern scientific knowledge, TGD studies and develops natural food supplements capable of guaranteeing the well-being of the entire body. Eugedin Complex is a product that strongly encompasses the company’s vision and philosophy. The product’s natural ingredients act together in a synergetic effect and boost the body’s autophagy process, the process that allows the cells to fight viruses.
get in touch
Should you want more details about our product and order requirements information kindly contact our sales team using the form below.